Chronic Kidney Disease: How Early Detection Stops Progression Before It's Too Late

Most people with chronic kidney disease (CKD) don’t know they have it - until it’s too late. By the time symptoms like fatigue, swelling, or nausea show up, the kidneys have already lost half their function. And yet, if caught early, chronic kidney disease can be slowed, stopped, or even reversed in many cases. The problem isn’t lack of tools - it’s lack of testing. Two simple blood and urine tests can catch CKD years before it becomes life-threatening. But too often, they’re not done together, or not done at all.

What Chronic Kidney Disease Really Means

The eGFR (estimated glomerular filtration rate) tells you how well your kidneys are filtering waste. A normal number is above 90. If it drops below 60 for three months or more, you’re in stage 3 or worse. But here’s the catch: eGFR alone misses up to 40% of early cases. Why? Because it’s based on creatinine, which varies wildly with muscle mass, age, diet, and even race. A fit 70-year-old might have a normal creatinine but still be leaking protein - a silent sign of damage.

That’s where uACR comes in. The urine albumin-to-creatinine ratio measures how much protein is escaping your kidneys. A value of 30 mg/g or higher means damage is happening, even if your eGFR is still in the normal range. This is the key to catching CKD in stages 1 or 2 - when you still have time to act.

The Two-Test Rule: Why One Test Isn’t Enough

Today, every major guideline - from KDIGO to the American Diabetes Association - says you need both tests. A 2022 study in the Annals of Internal Medicine found that over 68% of rural primary care providers still didn’t order both tests together. That’s not just a gap - it’s a blind spot.

Imagine someone with type 2 diabetes. They get a yearly blood test. Creatinine is normal. They’re told, “Your kidneys are fine.” But if their uACR is 85 mg/g - three times the danger threshold - they’re already in stage 1 CKD. Without the urine test, they’re flying blind.

That’s why the National Kidney Foundation and other groups now push the message: “It Takes 2.” You need eGFR and uACR. No exceptions. No shortcuts.

Stages of CKD: Why Early Matters More Than You Think

• Stage 1: eGFR ≥90, but uACR ≥30 - kidneys look fine on paper, but damage is already there.
• Stage 2: eGFR 60-89, uACR ≥30 - still early, still manageable.
• Stage 3a: eGFR 45-59 - mild to moderate loss.
• Stage 3b: eGFR 30-44 - moderate to severe loss.
• Stage 4: eGFR 15-29 - severe loss.
• Stage 5: eGFR <15 - kidney failure. Dialysis or transplant needed.

Here’s the truth: 60-70% of people caught in stages 1 or 2 can avoid progressing to stage 3 or worse - if they act fast. A 2021 study from the CREDENCE trial showed that adding an SGLT2 inhibitor (a class of diabetes drugs) to the treatment plan in stage 2 CKD with proteinuria cut the risk of kidney failure by 32%. That’s not a small win. That’s life-changing.

And it’s not just about drugs. Tight blood pressure control - keeping it under 130/80 - reduces progression risk by 27%, according to the SPRINT trial. Diet changes, stopping NSAIDs like ibuprofen, quitting smoking, and managing blood sugar all add up. But none of it works if you don’t know you’re at risk.

Who Should Be Tested - And How Often

• People with diabetes - type 1 after five years, type 2 at diagnosis.
• People with high blood pressure - check at every visit, full panel annually.
• Those with heart disease, obesity, or a family history of kidney failure.
• People over 60 - age is a major risk factor.
• African Americans, Native Americans, and Hispanic populations - these groups have 2-4 times higher risk.

And here’s something most don’t realize: if you’re over 85 with an eGFR of 45-59 but no proteinuria, you might not have true CKD. Aging kidneys naturally slow down. That’s why doctors now look at both tests - not just numbers. A 60-year-old with diabetes and uACR of 90? That’s urgent. An 88-year-old with no diabetes and uACR of 15? Probably not.

What Happens After Diagnosis?

1. Confirm with repeat testing. One abnormal result isn’t enough. Both tests must be abnormal for at least three months.
2. Control blood pressure. Aim for under 130/80. ACE inhibitors or ARBs are often first-line - they protect kidneys even if you don’t have high blood pressure.
3. Manage blood sugar. If you have diabetes, keep HbA1c under 7%. Newer drugs like SGLT2 inhibitors (empagliflozin, dapagliflozin) and GLP-1 agonists (semaglutide) are now standard for CKD patients with diabetes.
4. Reduce protein and salt. A diet low in sodium and processed protein helps. A registered dietitian can help tailor this - no need for extreme restrictions.
5. Avoid nephrotoxic drugs. NSAIDs (ibuprofen, naproxen), certain antibiotics, and contrast dyes for scans can damage kidneys. Ask your doctor before taking anything new.
6. Get educated. Patients who see visual charts of their kidney stage (like a traffic light system: green = safe, yellow = warning, red = danger) are 28% more likely to follow treatment plans.

One patient in Melbourne, diagnosed at stage 1 after a routine check-up, started on an SGLT2 inhibitor and cut salt intake. Five years later, her eGFR is still 92. Her uACR dropped from 85 to 12. She’s not cured - but she’s not declining either.

Why So Many Cases Are Still Missed

• Electronic health records don’t prompt for both tests. A 2023 survey found 63% of doctors say their systems don’t remind them to order uACR when eGFR is borderline.
• Doctors don’t know how to interpret the combo. One study found 22% of early CKD cases were misread because providers didn’t understand that normal eGFR + high uACR = early damage.
• Patients don’t ask. Most people think “kidney disease” means dialysis. They don’t realize it starts quietly.
• Insurance doesn’t always cover it. The U.S. Preventive Services Task Force still gives CKD screening an “I statement” - meaning insufficient evidence. That’s outdated. Medicare Advantage plans now reward clinics for catching early CKD - but not all insurers do.

There’s hope. In 2023, the FDA cleared the first AI tool - NephroSight by Renalytix - that predicts CKD risk using 32 data points before eGFR drops. The Biden administration is funding a $150 million push to make dual-testing mandatory in federally funded clinics by 2026. Australia and Japan have already cut end-stage kidney disease by 20% using systematic screening. We know how to fix this. We just need to do it.

What You Can Do Today

• Ask your doctor: “Have you checked my eGFR and uACR this year?”
• If they say “we only check creatinine,” ask: “Can we do the urine albumin test too?”
• Don’t wait for symptoms. CKD doesn’t hurt until it’s too late.
• Keep a record of your numbers. Track eGFR and uACR over time - even small drops matter.
• If you’re diagnosed with early CKD, don’t panic. You have years to act. Many people live full lives without ever needing dialysis.

Early detection isn’t about fear. It’s about control. You can’t change your age or your genes. But you can change what you test for - and what you do next.

If you’re diabetic, hypertensive, or over 60 - don’t wait for your doctor to bring it up. Ask for the two tests. Your future kidneys will thank you.